---
layout: minimal-medicine
title: Lumiracoxib
---

# Lumiracoxib
### Generic Name
Lumiracoxib

### Usage
Lumiracoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was primarily used to provide symptomatic relief from osteoarthritis (OA) of the hip and knee.  It works by selectively inhibiting cyclooxygenase-2 (COX-2), an enzyme involved in the production of prostaglandins, substances that contribute to pain and inflammation.  Due to safety concerns, however, lumiracoxib has been withdrawn from the market in many countries.  It is no longer widely available.

### Dosage
Because lumiracoxib is no longer widely available, providing specific dosage information would be irresponsible and potentially misleading.  **Do not attempt to obtain or use lumiracoxib without first consulting a doctor.**  The dosage would have varied depending on the individual patient, their condition, and the formulation (if any still exist).  If a doctor considers lumiracoxib in a specific, rare circumstance, they will determine the appropriate dose.

### Side Effects
While lumiracoxib is no longer on the market, it's important to understand its known side effects to inform future drug development and appreciate the reasons for its withdrawal.  Reported side effects included:

* **Common:** Headache, nausea, diarrhea, abdominal pain, dizziness, upper respiratory tract infections.
* **Serious (but less common):**  Liver damage (including potentially fatal liver failure),  heart attack, stroke,  kidney problems.

**If you experience any adverse effects, even those not listed here, seek immediate medical attention.**


### How it Works
Lumiracoxib is a selective COX-2 inhibitor.  COX-2 is an enzyme that plays a key role in inflammation and pain.  By selectively inhibiting COX-2, lumiracoxib reduces the production of prostaglandins, thereby lessening pain and inflammation associated with osteoarthritis.  Unlike older NSAIDs, lumiracoxib was designed to minimize its effects on COX-1, an enzyme important for protecting the stomach lining. However, this selectivity did not eliminate the risk of serious adverse events.


### Precautions
Given the serious risks associated with lumiracoxib and its withdrawal from the market, it is crucial to reiterate that it should not be used.  Before the withdrawal, precautions included:

* **Liver function monitoring:** Regular liver function tests were needed for patients taking lumiracoxib.
* **Cardiovascular risk:** Lumiracoxib carried a risk of cardiovascular events (heart attack and stroke) and therefore should not be used by patients with existing cardiovascular disease.
* **Kidney problems:** Patients with impaired kidney function should have used caution, and possibly avoided, lumiracoxib.
* **Pregnancy and breastfeeding:** Lumiracoxib was contraindicated during pregnancy and breastfeeding.
* **Drug interactions:**  Potential drug interactions existed, and a physician should always be consulted about other medications.


### FAQs

**Q: Is lumiracoxib still available?**

A: No, lumiracoxib has been withdrawn from the market in most, if not all, countries due to safety concerns, primarily the risk of serious liver damage.

**Q: What are the alternatives to lumiracoxib for osteoarthritis?**

A:  Many other treatments for osteoarthritis are available, including other NSAIDs (with careful consideration of their risks), paracetamol, topical analgesics, and other disease-modifying drugs.  A healthcare professional can help choose the most appropriate treatment.

**Q:  Why was lumiracoxib taken off the market?**

A:  The primary reason for the withdrawal was the unacceptable risk of serious liver damage, including liver failure requiring transplantation.  Additional concerns included the possibility of cardiovascular events.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice. Always consult a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided regarding Lumiracoxib reflects its past use and should not be interpreted as an endorsement of its current use.
